Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor

American Journal of Therapeutics

Volumn 7, Issue 3, 2000, Pages 159-175

  Whelton, A ^a,c   Maurath, C J ^b   Verburg, K M ^b   Geis, G S ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c Universal Clinical Research Center Inc   (United States)

Author keywords

Analgesic; Celecoxib; COX 2 specific inhibitors; Nephrotoxicity; Nonsteroidal anti inflammatory drugs; Renal safety

Indexed keywords

CELECOXIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

AGE; AGED; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG INTERACTION; EDEMA; FACTUAL DATABASE; HEART DISEASE; HUMAN; HYPERTENSION; KIDNEY; OSTEOARTHRITIS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR;

AGE FACTORS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE INHIBITORS; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EDEMA; HEART DISEASES; HUMANS; HYPERTENSION; KIDNEY; OSTEOARTHRITIS; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SULFONAMIDES;

EID: 0034189392     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-200007030-00004     Document Type: Article

References (86)

1. Simon LS, Lanza FL, Lipsky PE, et al: Preliminary study of the safety and efficacy of celecoxib, a novel cyclooxygenase 2 inhibitor. Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998;41:1591-1602.
2. Geis GS, Stead H, Morant SV, et al: Efficacy and safety of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum 1998;41(Suppl 9): S316:Abstract 1699.
3. Geis GS, Hubbard RC, Callison DA, et al: Safety and efficacy of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum 1998; 41(Suppl 9):S364:Abstract 1990.
4. Penning TD, Talley JJ, Bertenshaw SR, et al: Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). J Med Chem 1997;40:1347-1365.
5. O'Neill GP, Mancini JA, Kargman S, et al: Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetrae-noic acid. Mol Pharmacol 1994;45: 245-254.
6. Mitchell JA, Akarasereenont P, Thiemermann C, et al: Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A 1993;90:11693-11697.
7. Gierse JK, Hauser SD, Creely DP, et al: Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J 1995;305: 479-484.
8. Laneuville O, Breuer DK, De Witt DL, et al: Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 1994;271:927-934.
9. Agrawal NM, Van Kerckhove HEJM, Erhardt LJ, et al: Misoprostol co-administered with diclofenac for prevention of gastroduodenal ulcers. A one-year study. Dig Dis Sci 1995;40:1125-1131.
10. Gabriel SE, Jaakkimainen L, Bombardier C: Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991;115:787-796.
11. Garcia Rodriguez LA, Jick H: Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-772.
12. Langman MJS, Weil J, Wainwright P, et al: Risks of bleeding peptic ulcer associated with individual nonsteroidal anti-inflammatory drugs. Lancet 1994;343: 1075-1078.
13. Silverstein FE, Graham DY, Senior JR, et al: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-249.
14. Roth SH, Bennett RE, Caldron PH, et al: Endoscopic evaluation of the long term effects of diclofenac sodium and naproxen in elderly patients with arthritis. Clin Drug Invest 1995;9:171-179.
15. Roth SH, Bennett RE, Caldron PH, et al: Five-year comparative endoscopic evaluation of arthritis patients treated with nabumetone versus naproxen. Arthritis Rheum 1991;34(Suppl):S157.
16. Roth SH, Tindall EA, Jain AK, et al: A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med 1993;153:2565-2571.
17. Taha AS, Hudson N, Hawkey CJ, et al: Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal anti-inflammatory drugs. N Engl J Med 1996;334:1435-1439.
18. Schafer AI: Effects of nonsteroidal anti-inflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol 1995;35:209-219.
19. Goldman S, Copeland J, Moritz T, et al: Improvement in early saphenous vein graft patency after coronary artery bypass surgery with anti-platelet therapy: results of a Veterans Administration Co-operative Study. Circulation 1988;77:1324-1332.
20. Bashein G, Nessly ML, Rice AL, et al: Preoperative aspirin therapy and reoperation for bleeding after coronary artery bypass surgery. Arch Intern Med 1991;151: 89-93.
21. Green D, Davies RO, Holmes GI, et al: Effects of diflunisal on platelet function and fecal blood loss. Clin Pharmacol Ther 1981;30:378-384.
22. Taivainen T, Hiller A, Rosenberg PH, et al: The effect of continuous intravenous indomethacin infusion on bleeding time and postoperative pain in patients undergoing emergency surgery of the lower extremities. Acta Anaesthesiol Scand 1989;33:58-60.
23. Conrad KA, Fagan TC, Mackie MJ, et al: Effects of ketorolac tromethamine on hemostasis in volunteers. Clin Pharmacol Ther 1988;43:542-546.
24. Bashein G, Nessly ML, Rice AL, et al: Preoperative aspirin therapy and reoperation for bleeding after coronary artery bypass surgery. Arch Intern Med 1991;151: 89-93.
25. Clive DM, Stroff JS: Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984;310:563-572.
26. Murray MD, Black PK, Kuzmik DD, et al: Acute and chronic effects of nonsteroidal anti-inflammatory drugs on glomerular filtration rate in elderly patients. Am J Med Sci 1995;310:188-197.
27. Murray MD, Lazaridis EN, Brizendine E, et al: The effect of nonsteroidal anti-inflammatory drugs on electrolyte homeostasis and blood pressure in young and elderly persons with and without renal insufficiency. Am J Med Sci 1997;314:80-88.
28. Whelton A, Watson J: Non-steroidal anti-inflammatory drugs: effects on kidney function. In: Clinical Nephrotoxins: Renal Injury from Drugs and Chemicals. (Eds. De Broe ME, Porter GA, Bennet WM, Verpoooten GA), Kluwer Academic Publishers, Dordrecht, Netherlands, 1997, pp 209-222.
29. Whelton A, Hamilton CW: Non-steroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol 1991;31:588-598.
30. Whelton A, Stout RL, Spilman PS, et al: Renal effects of ibuprofen, piroxicam and sulindac in patients with asymptomatic renal failure: a prospective, randomized, crossover comparison. Ann Intern Med 1990;112:568-598.
31. Palmer BF: Renal complications associated with use of nonsteroidal anti-inflammatory agents. J Invest Med 1995;43:516-533.
32. Masferrer JL, Zweifel BS, Manning PT, et al: Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and non-ulcerogenic. Proc Natl Acad Sci U S A 1994;91:3228-3232.
33. Seibert K, Zhang Y, Leahy K, et al: Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci U S A 1994;91:12013-12017.
34. Fu J-Y, Masferrer JL, Seibert K, et al: The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990;265: 16737-16740.
35. Lee SH, Soyoola E, Chanmugam P, et al: Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 1992;267:25934-25938.
36. Jones DA, Carlton DP, McIntyre TM, et al: Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993;268:9049-9054.
37. Masferrer JL, Zweifel BS, Seibert K, et al: Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 1990;86:1375-1379.
38. Masferrer JL, Seibert K, Zweifel B, et al: Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci U S A 1992;89:3917-3921.
39. Kujubu DA, Herschman HR: Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/ cyclooxygenase gene. J Biol Chem 1992;267:7991-7994.
40. O'Banion MK, Sadowski HB, Winn V, et al: A serum-and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 1991;266: 23261-23267.
41. Futaki N, Yoshikawa K, Hamasaka Y, et al: NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol 1993;24:105-110.
42. Chan CC, Boyce S, Brideau C, et al: Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: A novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther 1995;274:1531-1537.
43. Anderson GD, Hauser SD, McGarity KL, et al: Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 1996;97:2672-2679.
44. Whelton A: Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999;106(5B):13S-24S.
45. Whelton A: Non-steroidal anti-inflammatory drugs: Effects on kidney function. In: Primer on Kidney Diseases. (Ed. Greenberg A), Academic Press, San Diego, 1994, pp 163-167.
46. Galler M, Folkert VW, Schlondorff D: Reversible acute renal insufficiency and hyperkalemia following indomethacin therapy. JAMA 1981;246:154-155.
47. Findling JW, Beckstrom D, Rawsthorne L, et al: Indomethacin-induced hyperkalemia in three patients with gouty arthritis. JAMA 1980;244:1127-1128
48. Akbarpour F, Afrasiabi A, Vaziri ND: Severe hyperkalemia caused by indomethacin and potassium supplementation. South Med J 1985;78:756-757.
49. Nicholls MG, Espiner EA: Indomethacin-induced azotaemia and hyperkalaemia: a case study. N Z Med J 1981;94:377-379.
50. Howes LG: Which drugs affect potassium? Drug Saf 1995;4:240-244.
51. Pérez Gutthann S, Garcia Rodriguez LA, Raiford DS, et al: Non-steroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure. Arch Intern Med 1996;156:2433-2439.
52. Evans JM, McGregor E, McMahon AD, et al: Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure. Q J Med 1995;88:551-557.
53. Clive DM, Stoff JS: Renal syndromes associated with non-steroidal anti-inflammatory drugs. N Engl J Med 1984;310:563-572.
54. Levin ML: Patterns of tubulo-interstitial damage associated with nonsteroidal anti-inflammatory drugs. Semin Nephrol 1988;8:55-61.
55. Abraham PA, Keane WF: Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. Am J Nephrol 1984;4:1-6.
56. Bender WL, Whelton A, Beschorner WE, et al: Interstitial nephritis, proteinuria, and renal failure caused by nonsteroidal anti-inflammatory drugs. Immunologic characterization of the inflammatory infiltrate. Am J Med 1984; 76:1006-1012.
57. Shah GM, Muhalwas KK, Winer RL: Renal papillary necrosis due to ibuprofen. Arthritis Rheum 1981;24:1208-1210.
58. Lourie SH, Denman SJ, Schroeder ET: Association of renal papillary necrosis and ankylosing spondylitis. Arthritis Rheum 1977;20:917-921.
59. Morales A, Steyn J: Papillary necrosis following phenylbutazone ingestion. Arch Surg 1971;103:420-421.
60. Husserl FE, Lange RK, Kantrow CM Jr: Renal papillary necrosis and pyelonephritis accompanying fenoprofen therapy. JAMA 1979;242:1896-1898.
61. Robertson CE, Ford MJ, Van Someren V, et al: Mefenamic acid nephropathy. Lancet 1980;2:232-233.
62. Pope JE, Anderson JJ, Felson DT: A meta-analysis of the effects of non-steroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993;153:477-184.
63. Johnson AG, Nguyen TV, Day RO: Do non-steroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994;121:289-300.
64. Ruoff GE: The impact of nonsteroidal anti-inflammatory drugs on hypertension; alternative analgesics for patients at risk. Clin Ther 1998:20:376-387.
65. Collins R, Peto R, MacMahon S, et al: Blood pressure, stroke and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335:765-774.
66. Brater DC: Diuretic therapy. N Engl J Med 1998;339:387-395.
67. Johnson AG, Seideman P, Day PO: Adverse drug reactions with non-steroidal anti-inflammatory drugs (NSAIDs). Drug Saf 1993;8:99-127.
68. Brown J, Dollery C, Vides G: Interaction of non-steroidal anti-inflammatory drugs with anti-hypertensive and diuretic agents. Am J Med 1986;81(Suppl 2b):43-57.
69. van den Ouweland FA, Gribnau FWJ, Meyboom RHB: Congestive heart failure due to non-steroidal anti-inflammatory drugs in the elderly. Age Ageing 1988;17: 8-16.
70. Heerdink ER, Leufkens HG, Herings RM, et al: NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 1998;158:1108-1112.
71. Whelton A, Schulman G, Wallemark C, et al: Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000;in press.
72. Oates JA, FitzGerald GA, Branch RA, et al: II: Clinical implications of prostaglandin and thromboxane A2 formation. N Engl J Med 1988;319:689-698.
73. Walshe JJ, Venuto RC: Acute oliguric renal failure induced by indomethacin: possible mechanisms. Ann Intern Med 1979;91:47-49.
74. Arisz L, Donker AJM, Brentjens JRH, et al: The effect of indomethacin on proteinuria and kidney function in the nephrotic syndrome. Acta Med Scand 1976;199:121-125.
75. Kleinknecht C, Broyer M, Gubler MC, et al: Irreversible renal failure after indomethacin in steroid-resistant nephrosis. N Engl J Med 1980;302:691.
76. Kimberly RP, Gill JR Jr, Bowden RE, et al: Elevated urinary prostaglandins and the effects of aspirin on renal function in lupus erythematosus. Ann Intern Med 1978; 89:336-341.
77. Fong HJ, Cohen AH: Ibuprofen-induced acute renal failure with acute tubular necrosis. Am J Nephrol 1982;2: 28-31.
78. Dinchuk JC, Car BD, Focht RJ, et al: Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase. Nature 1995;378:406-409.
79. Morham SG, Langenbach RL, Loftin CD, et al: Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995;83:473-482.
80. Zhang M-Z, Wang J-L, Cheng H-F, et al: Cyclooxygenase 2 in rat nephron development. Am J Physiol 1997;273: F994-F1002.
81. Harris RC, McKanna JA, Akai Y, et al: Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994;94:2504-2510.
82. Vio CP, Cespedes C, Gallardo P, et al: Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells. Hypertension 1997;30:687-692.
83. O'Neill GP, Ford-Hutchinson AW: Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993;330:156-160.
84. Kömhoff M, Gröne H-J, Klein T, et al: Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney; implication for renal function. Am J Physiol 1997; 272:F460-F468.
85. Guan Y, Chang M, Cho W, et al: Cloning, expression and regulation of rabbit cyclooxygenase-2 in renal medullary interstitial cells. Am J Physiol 1997;273:F18-F26.
86. Khan KNM, Venturini CM, Bunch RT, et al: Interspecies differences in renal localization of cyclooxygenase isoforms: implications in non-steroidal anti-inflammatory drug-related nephrotoxicity. Toxicol Pathol 1998;26:612-620.